A Phase 1b, Multicenter, Randomized, Placebo-controlled, Observer-blinded, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Sm-p80 + GLA-SE (SchistoShield ®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar.

Condition:   Schistosomiasis Intervention:   Biological: Sm-p80 + GLA-SE Sponsor:   International Vaccine Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials